Q-omics provides the consensus-scored OR2T5 profile across patient tissues and cancer cell-line models. OR2T5 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, OR2T5 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, OR2T5 RNA expression shows 4,656 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight STAD, KIRC, and ESCA as cancer lineages where OR2T5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2T5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2T5 survival associations across molecular data types. OR2T5 RNA expression shows survival associations in the most cancer types (6), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2T5 RNA expression–survival associations across cancer types. High OR2T5 expression shows unfavorable associations in STAD, UCEC, OV and GBM, but favorable associations in KIRC and KIRP. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for OR2T5 RNA expression.
This table summarizes OR2T5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR2T5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2T5 shows lower tumor expression in KIRP and KICH and higher tumor expression in KIRC. The KIRC box plot shows higher OR2T5 RNA expression in tumor versus normal tissue (log2 FC = +0.052, t-test p = .034).
This table shows molecular features associated with OR2T5 in patient tissues and cancer cell lines. In patient samples, OR2T5 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, OR2T5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
